BioNTech falls on outlook, departure of co-founders

BioNTech (BNTX) stock slides as 2026 revenue outlook misses forecasts and a CEO succession begins. Read more here ...

Scientists behind COVID-19 vaccine will depart BioNTech

The company’s co-founders said they are leaving to start a new mRNA-based company.

BioNTech’s founders will leave to start new firm with mRNA focus

BioNTech SE’s founders will leave the company to start a new biotech focused on messenger RNA, the technology behind their blockbuster Covid-19 vaccine.
Fierce Biotech

BioNTech's CEO, CMO prep departure to set up next-gen mRNA company

BioNTech’s CEO and his fellow co-founder will depart the biopharma by the end of the year to head up a new company focused on “next generation mRNA innovations.” Uğur Şahin, M.D., who is currently the ...
Devdiscourse

BioNTech Founders to Launch New Venture, Shifting Focus to mRNA-Driven Drug Discovery

BioNTech's co-founders, Ugur Sahin and Oezlem Tuereci, will leave the company by 2026 to establish a new venture focused on next-generation mRNA drugs. Although BioNTech's stock plummeted following ...

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by ...

BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA ...

BioNTech Shares Fall After Cofounders Plan Exit, Outlook Misses Forecasts

The stock was down 14% premarket after BioNTech announced the departures and issued revenue guidance that fell short of Wall Street’s forecasts.
Fierce Biotech

Pfizer's oncology R&D strategy: Jeff Legos on speed, breadth and novel combinations

Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...